Important note

This AI stock analysis for Tarsus Pharmaceuticals is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Tarsus Pharmaceuticals - AI Stock Analysis

Analysis generated March 23, 2025

Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative treatments for ophthalmic conditions. Their portfolio includes a robust pipeline of novel therapeutic candidates, with an emphasis on addressing unmet needs in eye care. Their focus on ocular conditions creates a niche market where they can leverage their scientific expertise and cutting-edge technology.

Fundamental Analysis

The revenue for the last quarter was $48 million, which represents a 17.90% increase from the previous quarter and a staggering 2,471.78% increase from the same quarter last year. This significant year-over-year growth suggests that Tarsus Pharmaceuticals is successfully scaling its operations and expanding its market reach.

Net income for the last quarter was $23 million. Compared to the previous quarter, this is an impressive 29.65% growth, and compared to the same quarter last year, it represents a 40.18% increase. This data suggests improving operational efficiencies and greater profit margins.

The EBITDA for the last quarter was $25 million, which shows a 24.52% increase compared to the previous quarter and a 34.98% increase compared to the same quarter last year. This signifies robust operational performance and an ability to generate substantial earnings before interest, taxes, depreciation, and amortization.

However, it's noteworthy that there have been recent insider stock sales, which could signal potential bearish sentiments from those within the company.

Technical Analysis

Today's stock price is $49.97, reflecting a 4.45% increase from a month ago and a 48.68% increase from a year ago. The bullish trend is evident in these gains. The current Simple Moving Average over 10 days (SMA10) is $48.73, which is higher than the previous SMA10 of $48.38, suggesting a potential upward price movement.

The Relative Strength Index (RSI) stands at 60.4, indicating a neutral condition. An RSI between 30 and 70 generally suggests that the stock is neither overbought nor oversold, providing a balanced outlook for investors.

Alternative Data Analysis

Examining job postings and employee sentiment, Tarsus Pharmaceuticals has 23 open positions, which have grown by 53% in the last couple of months. This implies expansion and growth within the company. Further, the business outlook among employees is extremely positive, with an estimate of 100% of employees having a favorable outlook, highlighting strong internal confidence in the company's future.

However, there are some concerning trends in customer acquisition metrics. The website visitor count is estimated at 13,000, which is down by 77% in the last couple of months. This decline might indicate potential issues in customer retention or interest. On the other hand, customer engagement seems stable with social media metrics showing a slight increase in Instagram followers by 3% to a total of 1,100 followers. The Twitter follower count remains at 620 with no significant changes.

Lastly, considering the AltIndex AI score, which integrates fundamental, technical, and alternative data analyses, Tarsus Pharmaceuticals has an AI score of 73, indicating a buy signal.

Conclusion

In summary, Tarsus Pharmaceuticals exhibits strong fundamental growth evidenced by significant increases in revenue, net income, and EBITDA. The technical analysis supports a bullish trend with a stock price increase and favorable SMA and RSI indicators. Alternative data presents a mixed picture with substantial growth in job postings and positive employee sentiment, but declining website traffic. The AltIndex AI score of 73 further reinforces a positive outlook for the stock.

Given the comprehensive analysis, Tarsus Pharmaceuticals demonstrates strong growth potentials albeit with some cautions, particularly in customer acquisition metrics. Investors are advised to consider these factors carefully when making investment decisions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.